Faculty
Mark Schroeder.jpg

Mark A. Schroeder, MD

Assistant Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Hematologic malignancies including multiple myeloma
  • Hematopoietic stem cell transplantation
  • Transplant for sickle cell disease

Research Interests

  • Transplant biology
  • Graft-versus-host disease
  • Graft-versus-tumor effects
  • Stem cell mobilization

Contact

  • 314-454-8323 (office)
  • 314-362-9335 (lab)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Washington University Medical School
    660 South Euclid Avenue
    Campus Box 8007
    Saint Louis, MO 63110

Bibliography

  • Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo
    Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, DiPersio JF
    J Immunol 2017 May 1;198(9):3746-3754
  • Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 Mar 14; [Epub ahead of print]
  • T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • A proposed biology- and biomarker-based algorithm for management of acute GvHD
    Ali AM, DiPersio JF, Schroeder MA
    Bone Marrow Transplant 2017 Feb;52(2):337-340
  • Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 Jan 9; [Epub ahead of print]
  • TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review
    Ali AM, DiPersio JF, Schroeder MA
    Biol Blood Marrow Transplant 2016 Sep;22(9):1552-64
  • Peritransplant serum albumin decline predicts subsequent severe acute graft-versus-host disease after mucotoxic myeloablative conditioning
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Cashen AF, Pusic I, Romee R
    Biol Blood Marrow Transplant 2016 Jun;22(6):1137-41
  • Do somatic mutations in de novo MDS predict for response to treatment?
    Schroeder MA, DeZern AE
    Hematology Am Soc Hematol Educ Program 2015 Dec 5;2015(1):317-28
  • Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Mobilization of hematopoietic stem and leukemia cells
    Schroeder MA, Dipersio JF
    J Leukoc Biol 2012 Jan;91(1):47-57
  • Mouse models of graft-versus-host disease: advances and limitations
    Schroeder MA, DiPersio JF
    Dis Model Mech 2011 May;4(3):318-33
  • Myelodysplastic syndromes
    Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P
    J Natl Compr Canc Netw 2011 Jan;9(1):30-56
  • Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?
    Schroeder MA, Blum W
    Hematology Am Soc Hematol Educ Program 2010;2010:322-4